So where do we go from here, page-33

Exactly, will not be very expensive

Also go back to the last few releases ie agm and investor update

The last 4D flagged the agreement with the manufacturer.
The investor update prior to that talked about an MTA in place with a UK distributor who is assessing in there own labs. Next step is regulatory clearance and if successful and the lab work is also proven, then they more than likely have a UK distributor. If they have there own Lab testing then I would imagine they are quite large and not your run of the mill wholesale distributor.

Now having a distributor is not like going it alone and distributing it yourself like POH did through the chemist chain.

The distributor has the sales team, will more than likely drive the marketing/advertising and logistics (again depends on the deal), obviously they will recover that cost.

Given the timing, a cap raise is very unlikely. OBJ is about to be cash positive with three more products before 2020. Also given the reaction to the last raise (failure). If anything it would be a small placement.

IMO